Subs	Substitute for form 1449A/PTO			Complete if Known		
				Application Number	09/432,503	
				Filing Date	November 2, 1999	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			First Named Inventor	Cech, Thomas R.	
Si				Art Unit	1635	
	(Use as many sheets as ne	cessar	v)	Examiner Name	Jon E. Angell	
Sheet	1	of	2	Attorney Docket Number	015389-002611US	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number Kind Code ² (Fincent)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1	US 4 889 806	12-26-1989	Olson et al.			

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶			

Examiner	Date	
Signature	Considered	
Oignature		

EXAMINER: Initial if reference considered, whether or not clasten is in conformance with NIEF 800. Draw line through clasted of not in conformance and not considered. Include copy of the form with normalization on prilingent. * *Applicant project project existent designation number (normal). *Normalization of the conformation of the Conformatio

Substitute	o for form 1449B/PTO	1		Complete if Known			
				Application Number	09/432,503		
INFC	RMATION D	DISCLOS	URE	Filing Date	November 2, 1999		
STA	STATEMENT BY APPLICANT			First Named Inventor	Cech, Thomas R.		
				Art Unit	1635		
	(Use as many sheets	as necessary)		Examiner Name	Jon E. Angell		
Sheet	2	of	2	Attorney Docket Number	015389-002611US		

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	2	ABAZA, M. et al., "Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 94-100 (antigenic site 3) of myoglobin," J. Prot. Chem. 11(5):433-44 (1992).					
	3	COLMAN, P., "Effects of amino acid sequence changes on antibody-antigen interactions," Res. Immunol. 145(1):33-6 (1994).					
		HARLOW, E. & LANE, D., <u>Antibodies, A Laboratory Manual</u> , Cold Spring Harbor Laboratory Press, pp. 93-94, 142, 238 (1988).					
	5	HERBERT, J. et al., <u>The Dictionary of Immunology</u> , 4 th Edition, Academic Press, London, p. 58 (1995).					
	6	ISHIKAWA, F. & NAKAYAMA, J., "A mammalian telomerase component gene TLP1," Protein Nucleic Acid and Enzyme 42(9):1407-19 (July 1997). Japanese Language document WITH English Translation of Abstract.	Ø				
	7	TAKANO, M. & ISHİKAWA, F., The Adjustment Foundation of Science and Technology Promotion News, Vol. 160, pp. 0-6 (July 11, 1997). Japanese language document WITH English Translation of Abstract.	Ø				
	8	TANAKA, T. et al., "Efficient generation of antibodies to oncoproteins by using synthetic peptide antigens," <i>Proc. Natl. Acad. Sci. USA 82</i> :3400-4 (1985).					
	9	TATEMATSU, K. et al., <i>Tissue Culture 23</i> (1):4-11 (Jan 1997). Japanese language document WITH English Translation of Introduction.	\boxtimes				

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

"Applicants unjug citation designation number (options)", Applicant is to place a check mark here if English language Translation is attached.